Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma
暂无分享,去创建一个
P. Wang | Peng Wang | Justine Lai | Will Chen | M. Haque | Chuquan Shang | Raymond Lai
[1] A. Rosenwald,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.
[2] P. Limonta,et al. Cancer Stem Cells—Key Players in Tumor Relapse , 2021, Cancers.
[3] F. Meggetto,et al. NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target , 2021, Cancers.
[4] R. Lai,et al. Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent , 2021, Cancers.
[5] P. Ma,et al. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy , 2019, Journal of Hematology & Oncology.
[6] L. Medeiros,et al. MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients , 2019, Blood.
[7] C. Mullighan,et al. Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL , 2019, Blood.
[8] S. Turner,et al. NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma , 2019, Cancers.
[9] G. J. Yoshida. Emerging roles of Myc in stem cell biology and novel tumor therapies , 2018, Journal of Experimental & Clinical Cancer Research.
[10] R. Lai,et al. Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma , 2018, BMC Cancer.
[11] T. S. Ramasamy,et al. Cancer stem cells as key drivers of tumour progression , 2018, Journal of Biomedical Science.
[12] Š. Pospíšilová,et al. The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability , 2018, Cancers.
[13] A. Shaw,et al. Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.
[14] L. Michaux,et al. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene , 2017, Haematologica.
[15] L. Vitagliano,et al. Structural investigation of nucleophosmin interaction with the tumor suppressor Fbw7γ , 2017, Oncogenesis.
[16] W. Chan,et al. Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma. , 2017, Cancer cell.
[17] Dachuan Huang,et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. , 2017, Blood.
[18] M. Wasik,et al. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. , 2017, Blood.
[19] L. Fagnocchi,et al. Multiple Roles of MYC in Integrating Regulatory Networks of Pluripotent Stem Cells , 2017, Front. Cell Dev. Biol..
[20] N. Kneteman,et al. A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma , 2016, Journal of Hematology & Oncology.
[21] S. Turner,et al. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency , 2016, Oncogene.
[22] C. Dang,et al. MYC, Metabolism, and Cancer. , 2015, Cancer discovery.
[23] P. Wang,et al. NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair , 2015, Blood Cancer Journal.
[24] D. Felsher,et al. MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.
[25] K. Elenitoba-Johnson,et al. Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. , 2013, Blood.
[26] C. Dang. MYC, metabolism, cell growth, and tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.
[27] L. Meltesen,et al. Dual ALK and MYC Rearrangements Leading to an Aggressive Variant of Anaplastic Large Cell Lymphoma , 2013, Journal of pediatric hematology/oncology.
[28] S. R. Hann,et al. Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription , 2013, Oncogene.
[29] L. Pusztai,et al. Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.
[30] David E. Muench,et al. c-Myc and Cancer Metabolism , 2012, Clinical Cancer Research.
[31] M. Hitt,et al. Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma , 2012, Blood Cancer Journal.
[32] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[33] Y. Hoki,et al. Crucial Role of C‐Myc in the Generation of Induced Pluripotent Stem Cells , 2011, Stem cells.
[34] G. Delsol,et al. Inhibition of Rac controls NPM–ALK-dependent lymphoma development and dissemination , 2011, Blood cancer journal.
[35] B. Clurman,et al. Nucleolar Targeting of the Fbw7 Ubiquitin Ligase by a Pseudosubstrate and Glycogen Synthase Kinase 3 , 2011, Molecular and Cellular Biology.
[36] M. Freedman,et al. Chromosome 8q24-Associated Cancers and MYC. , 2010, Genes & cancer.
[37] David N. Boone,et al. Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation , 2008, Proceedings of the National Academy of Sciences.
[38] P. Pelicci,et al. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ , 2008, The Journal of cell biology.
[39] G. Delsol,et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas , 2008, Oncogene.
[40] L. Armengol,et al. Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility , 2008, BMC Genomics.
[41] R. Lai,et al. Pathobiology of ALK+ anaplastic large-cell lymphoma. , 2007, Blood.
[42] S. Cook,et al. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. , 2007, Cellular signalling.
[43] S. Monaco,et al. Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c‐myc rearrangement terminating in a leukemic phase , 2007, American journal of hematology.
[44] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[45] D. Gilliland,et al. Cell Proliferation Induced by the NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Is Mediated by mTOR/S6K1 and MEK/ERK Signaling. , 2004 .
[46] B. Clurman,et al. A Nucleolar Isoform of the Fbw7 Ubiquitin Ligase Regulates c-Myc and Cell Size , 2004, Current Biology.
[47] T. McDonnell,et al. Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma , 2004, Oncogene.
[48] R. Sears. The Life Cycle of C-Myc: From Synthesis to Degradation , 2004, Cell cycle.
[49] J. Griffin,et al. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. , 2004, Blood.
[50] K. Nakayama,et al. Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.
[51] G. Delsol,et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. , 2003, Blood.
[52] K. Pulford,et al. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.
[53] S. Pittaluga,et al. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. , 1996, Blood.
[54] R. Eisenman,et al. Expression of the c-myc proto-oncogene during development of Xenopus laevis , 1986, Molecular and cellular biology.
[55] R. Eisenman,et al. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells , 1984, Molecular and cellular biology.
[56] A. Rosenwald,et al. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. , 2015, Blood.
[57] R. Sears,et al. MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.